scholarly journals A phase 1, randomised, open-label, four-period crossover, single-dose study to evaluate the pharmacokinetics of hydrocortisone modified release tablets

2015 ◽  
Author(s):  
Gudmundur Johannsson ◽  
Hans Lennernas ◽  
Claudio Marelli ◽  
Kevin Rockich ◽  
Stanko Skrtic
Keyword(s):  
Single Dose ◽  
Phase 1 ◽  
Modified Release ◽  
Open Label ◽  
Single Dose Study ◽  
Dose Study

A phase 1, open-label, single-dose study of the pharmacokinetics of zanubrutinib in subjects with varying degrees of hepatic impairment

2020 ◽  
Vol 61 (6) ◽  
pp. 1355-1363
Author(s):  
Ying C. Ou ◽  
Richard A. Preston ◽  
Thomas C. Marbury ◽  
Zhiyu Tang ◽  
William Novotny ◽  
...  
Keyword(s):  
Single Dose ◽  
Hepatic Impairment ◽  
Phase 1 ◽  
Open Label ◽  
Single Dose Study ◽  
Dose Study

scholarly journals A phase-1, open-label, single-dose study of the pharmacokinetics of buparlisib in subjects with mild to severe hepatic impairment

2015 ◽  
Vol 56 (3) ◽  
pp. 316-323 ◽  
Author(s):  
Denes Csonka ◽  
Katharine Hazell ◽  
Edward Waldron ◽  
Sebastien Lorenzo ◽  
Vincent Duval ◽  
...  
Keyword(s):  
Single Dose ◽  
Hepatic Impairment ◽  
Phase 1 ◽  
Severe Hepatic Impairment ◽  
Open Label ◽  
Single Dose Study ◽  
Dose Study

1027-P: A Phase 1, Open-Label, Single-Dose Study to Evaluate Pharmacokinetics of MEDI0382 in Patients with Renal Impairment

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 1027-P
Author(s):  
GERNOT K. KLEIN ◽  
MARCELLA PETRONE ◽  
YE YANG ◽  
THUONG HOANG ◽  
SHEILA DICOSTANZA ◽  
...  
Keyword(s):  
Single Dose ◽  
Renal Impairment ◽  
Phase 1 ◽  
Open Label ◽  
Single Dose Study ◽  
Dose Study

scholarly journals A Phase 1, Randomized Ascending Single-Dose Study of Antagonist Anti-Human CD40 ASKP1240 in Healthy Subjects

2013 ◽  
Vol 13 (4) ◽  
pp. 1040-1046 ◽  
Author(s):  
R. Goldwater ◽  
J. Keirns ◽  
P. Blahunka ◽  
R. First ◽  
T. Sawamoto ◽  
...  
Keyword(s):  
Single Dose ◽  
Healthy Subjects ◽  
Phase 1 ◽  
Single Dose Study ◽  
Dose Study

scholarly journals A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis

2011 ◽  
Vol 79 (11) ◽  
pp. 1236-1243 ◽  
Author(s):  
Howard Trachtman ◽  
Fernando C. Fervenza ◽  
Debbie S. Gipson ◽  
Peter Heering ◽  
David R.W. Jayne ◽  
...  
Keyword(s):  
Single Dose ◽  
Focal Segmental Glomerulosclerosis ◽  
Phase 1 ◽  
Treatment Resistant ◽  
Single Dose Study ◽  
Segmental Glomerulosclerosis ◽  
Dose Study
Sign in / Sign up

Export Citation Format

Share Document